Professor Stephanie BaldewegProfessor Stephanie Baldeweg

Professor Stephanie Baldeweg works as a Consultant Physician in Diabetes and Endocrinology at University College London Hospital and as Honorary Professor at UCL. She is Clinical Lead of the Department of Diabetes & Endocrinology at UCLH. She graduated from Humboldt University Berlin in 1990 and received her MD in 2002 in London. In 2009 she was elected Fellow of the Royal College of Physicians of Ireland and of the Royal College of Physicians in London (FRCP). She has held a number of National Roles including Associate Academic Dean, Health Education England and Associate Director for Higher Specialties Training, UCL Partners. She is chair of the Clinical Committee, UK Society for Endocrinology and chair of the Joint Specialty Committee for Endocrinology and Diabetes at the Royal College of Physicians.

Professor Baldeweg is interested in all aspects of diabetes and endocrinology. She has a special clinical and research interest in pituitary disease. Her other interests include diabetes, thyroid and reproductive as well as osteoporosis, weight management and cardiovascular risk reduction. She also has an interest in pregnancy preparation for women with diabetes and endocrine disease. Her main academic interest aims to improve patient care through systematic clinical research with a focus on cross-specialty working and comorbidities.

Prof Baldeweg is a keen medical educator and regularly lectures at national and international meetings as well as Patient days for UK charities She is a trustee of The Pituitary Foundation.

Return to Top of Page - Return to Programme

Professor John Cunningham Professor John Cunningham

Professor John Cunningham is a clinician-scientist holding positions as Professor of Nephrology at University College London Medical School and The Royal Free Hospital and an Honorary Fellowship at Trinity Hall, University of Cambridge, both in the UK. His early training was in Cambridge (pre-clinical) and Oxford, UK (clinical), with postgraduate training at The University of London and Washington University School of Medicine, St Louis, USA under Drs Louis V Avioli and Eduardo Slatopolsky. He has remained an active frontline clinician in both nephrology and internal medicine. John Cunningham was Physician to HM The Queen and was knighted for services to The Royal Family in June 2014.

Academically Professor Cunningham has contributed to the understanding of the effect of acidosis on the bioactivation of vitamin D and described and characterised hysteresis in the parathyroid response to calcium, indicating that parathyroid cells can sense both the direction of change and the absolute concentration of ECF calcium. He subsequently ran research programmes examining the following: control by structurally modified vitamin D metabolites at PTH synthesis and release; the synthesis and release of bone cytokines by osteoblast like cells and the regulation of these by vitamin D metabolites; the location and relevance of the calcium sensing receptor in bone cells; the influence of simulated uraemia on the release of cytokines by bone cells; the factors mediating bone loss following renal transplantation and preventative strategies; the factors that control parathyroid function in vivo, including new vitamin D metabolites and calcimimetic agents. Professor Cunningham’s group has found that new structurally modified metabolites of vitamin D differ markedly in the way they influence the behaviour of both parathyroid cells and bone cells. His group also devised, conducted and published studies of the first effective prophylaxis against bone loss in the post transplant setting. On these and other subjects, Professor Cunningham frequently lectures nationally and internationally, as well as serving on numerous international expert panels and working groups. He is a founding Co-chairman of the Nephrology At The Limits series held under the auspices of University College London, The University of Cape Town, and The Lancet.

Return to Top of Page - Return to Programme

Dr Richard Horton Dr Richard Horton

Richard Horton is Editor-in-Chief of The Lancet. He was born in London and is half Norwegian. He qualified in physiology and medicine with honours from the University of Birmingham in 1986. He joined The Lancet in 1990, moving to New York as North American Editor in 1993. Richard was the first President of the World Association of Medical Editors and he is a Past-President of the US Council of Science Editors. He is an honorary professor at the London School of Hygiene and Tropical Medicine, University College London, and the University of Oslo. He has received honorary doctorates in medicine from the University of Birmingham, UK, the Universities of Gothenburg and Umea in Sweden, and the University of Tromso, Norway.

In 2016, he chaired the Expert Group for the High Level Commission on Health Employment and Economic Growth, convened by Presidents Hollande of France and Zuma of South Africa. From 2011 to 2015, he was co-chair of the UN's independent Expert Review Group on Information and Accountability for Women's and Children's Health. Richard has received the Edinburgh Medal (2007) and the Dean’s Medal from Johns Hopkins School of Public Health (2009). In 2011, he was elected a Foreign Associate of the US Institute of Medicine and, in 2015, he received the Friendship Award from the Government of China. He was awarded an Honorary Fellowship by the British Pharmacological Society (2016), the Andrija Stamper medal from the Association of Schools of Public Health in the European region (2017), the Edwin Chadwick Medal for outstanding contributions to the advancement of public health (2017), the WHO Director-General’s Health Leaders Award for outstanding leadership in global health (2019), and the Roux Prize in recognition of innovation in the application of global health evidence (2019).

He has written two reports for the Royal College of Physicians of London: Doctors in Society (2005) and Innovating for Health (2009). He wrote Health Wars (2003) about contemporary issues in medicine and health, and he has written for The New York Review of Books and the TLS. He has a strong interest in global health and medicine’s contribution to our wider culture. He now works to develop the idea of planetary health – the health of human civilizations and the ecosystems on which they depend.

Return to Top of Page - Return to Programme

Professor Derek Yellon Professor Derek Yellon

PhD, DSc (UK), DSc (UCT), FRCP (Hon), FACC, FESC, FAHA, is Professor of Molecular & Cellular Cardiology at University College London (UCL) & Director of the Hatter Cardiovascular Institute at UCL Hospitals & Medical School. He is also Programme Director (Cardiology & Diabetes) for the NIHR-UCLH Biomedical Research Centre.

He is past Vice President of the British Cardiovascular Society and past Chairman of the Cellular Biology Working Group of the European Society of Cardiology as well as past member of the World Council of the International Society for Heart Research. He was recently elected to Department of Health’s National Institute for Health Research (NIHR) as a Senior Investigator as well as a member of the College of Senior Investigators. In 1994 he was awarded a DSc for his “substantial contribution to the knowledge of cardiovascular disease and treatment”. In 2013 been awarded a second Doctor of Science (honorius causa) degree from the University of Cape Town in recognition of his distinguished basic and clinical research in the mechanisms underlying myocardial protection.

Professor Yellon was instrumental in establishing the Hatter Cardiovascular Institute at the Medical School of the University of Cape Town. In recognition of these achievements he was, in 1997, made an Hon. Professor in the Department of Medicine at the University of Cape Town. He also holds Honorary Professorships at the University of South Alabama in the USA, and the North China Coal Medical University in China.

He is a Fellow of the Royal College of Physicians; the American College of Cardiology; the European Society of Cardiology; the International Society for Heart Research and the American Heart Association.

He is on the editorial board of a number of major Cardiovascular Journals and has published in excess of 500 full papers and edited 23 books. He runs a translational research Institute with his main area of interest including; myocardial protection, the pathophysiology of cardioprotection in the setting of diabetes, ischaemia/reperfusion injury, molecular aspects of adaptation to ischaemic injury and myocardial conditioning in both the basic and clinical arena.

Return to Top of Page - Return to Programme